Rotigotine Attenuates Mechanical Hypersensitivity in 6-OHDA-Lesioned Rats: Associations with D2/D3 Receptors and Spinal Glial NF-κB/p65 Signaling
- 1Departamento de Sistemas Biológicos, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, Colonia Villa Quietud, Ciudad de México, 04960 México
- 2Departamento de Neurobiología del Desarrollo y Neurofisiología, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus UNAM Juriquilla, Querétaro, 76230 México
Abstract
Pain is a debilitating non-motor symptom of Parkinson’s disease (PD). This study investigated whether rotigotine attenuated pain hypersensitivity (allodynia and hyperalgesia) in hemiparkinsonian rats and explored D1/D2/D3 receptor involvement, NF-κB/p-p65 signaling modulation in glial cells, and spinal TNF-α and IL-1β expression. The PD model was induced by unilateral 6-OHDA injection into the substantia nigra pars compacta (SNpc). Pain sensitivity was assessed using von Frey filaments. Immunohistochemistry and immunofluorescence were used to analyze tyrosine hydroxylase levels in the SNpc and striatum, GFAP, Iba-1, and NF-κB/p-p65 expression in the dorsal horn of the L5 spinal cord, and ELISA was used to determine TNF-α and IL-1β levels in the lumbar spinal cord. Both acute (8 h) and subacute (5-day) intranasal rotigotine (0.1, 0.5, 0.75, and 1 mg/kg) showed antiallodynic and antihyperalgesic effects. These effects were prevented by selective D2 (L-741,626; 14.6 nmol) and D3 (nafadotride; 3 nmol) receptor antagonists, but not by the D1 receptor antagonist SCH-23,390 (30 nmol). Subacute rotigotine was associated with reduced 6-OHDA-induced glial activation, decreased NF-κB/p-p65 expression, and attenuated spinal TNF-α and IL-1β levels. Molecular docking suggests a potential interaction between rotigotine and the p65 subunit of NF-κB, with favorable binding energy. In conclusion, rotigotine moderated PD-related pain, potentially through D2/D3 receptor activation and modulation of neuroinflammation. This suggested antinociceptive effect may be linked to suppressing glial activation and inhibiting spinal astrocytes’ NF-κB/p-p65 signaling, potentially reducing subsequent proinflammatory cytokine release. These findings suggest that rotigotine may represent a promising therapeutic option for managing sensory hypersensitivity in PD.
Related
- 3D CNN-CVAE and LSTM-guided de novo design of rotigotine derivatives targeting dopamine D1 and D3 receptors in restless legs syndrome
- Boldine Attenuates Mechanical Allodynia and Mitigates Transcriptomic Changes in a Mouse Model of Chronic Constriction Injury
- Hydroethanolic Montanoa bipinnatifida Leaf Extract Attenuates Acute Ethanol-Induced Gastric Mucosal Injury in Female CD-1 Mice: Associations with Lipid Peroxidation and IL-1β Expression
- Associations between inflammatory-lipid indices and clinical outcomes in ischemic stroke patients treated with mechanical thrombectomy
- Targeting neuronal FKBP5 attenuates mechanical allodynia by suppressing NF-κB-mediated neuroinflammation in an NTG-induced chronic migraine mouse model.
BibTeX
@article{santamariaanzures2026rotigotine,
title = {{Rotigotine Attenuates Mechanical Hypersensitivity in 6-OHDA-Lesioned Rats: Associations with D2/D3 Receptors and Spinal Glial NF-κB/p65 Signaling}},
author = {Jazmin Santamaria-Anzures and Guadalupe Martínez-Lorenzana and Estefanía González-Morales and Dafne Palmeros-Barreda and Ledy De-la-Cruz-Martínez and Francisco Cortés-Benítez and Julia Pérez-Ramos and Miguel Condés-Lara and Beatriz Godínez-Chaparro},
journal = {Neurochemical Research},
year = {2026},
month = nov,
doi = {10.1007/s11064-026-04948-8},
url = {https://doi.org/10.1007/s11064-026-04948-8},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Rotigotine Attenuates Mechanical Hypersensitivity in 6-OHDA-Lesioned Rats: Associations with D2/D3 Receptors and Spinal Glial NF-κB/p65 Signaling
AU - Jazmin Santamaria-Anzures
AU - Guadalupe Martínez-Lorenzana
AU - Estefanía González-Morales
AU - Dafne Palmeros-Barreda
AU - Ledy De-la-Cruz-Martínez
AU - Francisco Cortés-Benítez
AU - Julia Pérez-Ramos
AU - Miguel Condés-Lara
AU - Beatriz Godínez-Chaparro
PY - 2026
DA - 2026/11/04
JO - Neurochemical Research
DO - 10.1007/s11064-026-04948-8
UR - https://doi.org/10.1007/s11064-026-04948-8
AB - Pain is a debilitating non-motor symptom of Parkinson’s disease (PD). This study investigated whether rotigotine attenuated pain hypersensitivity (allodynia and hyperalgesia) in hemiparkinsonian rats and explored D1/D2/D3 receptor involvement, NF-κB/p-p65 signaling modulation in glial cells, and spinal TNF-α and IL-1β expression. The PD model was induced by unilateral 6-OHDA injection into the substantia nigra pars compacta (SNpc). Pain sensitivity was assessed using von Frey filaments. Immunohistochemistry and immunofluorescence were used to analyze tyrosine hydroxylase levels in the SNpc and striatum, GFAP, Iba-1, and NF-κB/p-p65 expression in the dorsal horn of the L5 spinal cord, and ELISA was used to determine TNF-α and IL-1β levels in the lumbar spinal cord. Both acute (8 h) and subacute (5-day) intranasal rotigotine (0.1, 0.5, 0.75, and 1 mg/kg) showed antiallodynic and antihyperalgesic effects. These effects were prevented by selective D2 (L-741,626; 14.6 nmol) and D3 (nafadotride; 3 nmol) receptor antagonists, but not by the D1 receptor antagonist SCH-23,390 (30 nmol). Subacute rotigotine was associated with reduced 6-OHDA-induced glial activation, decreased NF-κB/p-p65 expression, and attenuated spinal TNF-α and IL-1β levels. Molecular docking suggests a potential interaction between rotigotine and the p65 subunit of NF-κB, with favorable binding energy. In conclusion, rotigotine moderated PD-related pain, potentially through D2/D3 receptor activation and modulation of neuroinflammation. This suggested antinociceptive effect may be linked to suppressing glial activation and inhibiting spinal astrocytes’ NF-κB/p-p65 signaling, potentially reducing subsequent proinflammatory cytokine release. These findings suggest that rotigotine may represent a promising therapeutic option for managing sensory hypersensitivity in PD.
SN - 0364-3190
SN - 1573-6903
ER -